Thin Gingival Biotype
Conditions
Brief summary
Randomized split mouth clinical trials study focused on comparing the efficacy of i-prf versus c-prf injections on gingival thickness and keratinized tissue width in subjects with thin gingival biotype.
Detailed description
Randomized split mouth clinical trials study focused on comparing the efficacy of i-prf versus c-prf injections on gingival thickness and keratinized tissue width in subjects with thin gingival biotype. Gingival biotype is an important clinical parameter that plays an important role in determining the gingival health in the future and the possibility of developing gingival recession or other gingival unhealthy condition that is related to thin gingival biotype. Gingival biotype is consist of gingival thickness and keratinized tissue width, and its either thin or thick, and the later is more favourable to withstand the developing of gingival diseases and unhealthy condition, with this study we compare the effect of i-PRF injection which is approved in many previous clinical trials that it affects the gingival biotype and increases gingival thickness and the keratinized tissue width, and compare it to newly developed PRF generation (C-PRF) which is Concentrated Platelet Rich Fibrin.
Interventions
OTHERPlatelets Rich Fibrin (i-PRF / C-PRF)
one site of the mouth will be injected with i-PRF and the other site will be injected with C-PRF
Sponsors
Sajjad Ahmed Shakir
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Age ≥18 years and no systemic disease or pregnancy. 2. Non-smoker. 3. Subjects with clinically healthy intact periodontium; bleeding on probing (BOP)\<10%, probing pocket depth (PPD)≤3mm, intact periodontium (no probing attachment loss). (Chapple et al., 2018). 4. Four non-adjacent sites of anterior region with thin gingival biotype (GT ≤ 1mm). (Patrick H. et al., 2018). 5. No malocclusion, crowding, filling, missing or supernumerary mandibular anterior teeth. 6. No blood-borne conditions. 7. Any symptoms of recent acute illness e.g., COVID-19.
Exclusion criteria
1. Active orthodontic treatment. 2. Previous periodontal surgery. 3. Use of blood thinners. 4. Use of any drugs that might lead to gingival enlargement. 5. Attrition. 6. Gingival Recession. 7. Thick gingival biotype.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| measure the mean differences gain of GT&KTW | baseline and 3 months | the increase in gingival thickness and keratinized tissue width after the injection of prf concentrates. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| measure the mean difference gain of GT&KTW | baseline and 1 month | the increase in gingival thickness and keratinized tissue width after the injection of prf concentrates. |
Countries
Iraq
Outcome results
None listed